BAFNAPH

Bafna Pharmaceuticals Share Price

 

 

Start SIP in BAFNAPH

Start SIP

Performance

  • Low
  • ₹145
  • High
  • ₹153
  • 52 Week Low
  • ₹69
  • 52 Week High
  • ₹202
  • Open Price₹148
  • Previous Close₹148
  • Volume2,574

Investment Returns

  • Over 1 Month -0.03%
  • Over 3 Month -12.49%
  • Over 6 Month + 65.73%
  • Over 1 Year + 83.01%

Smart Investing Starts Here Start SIP with Bafna Pharmaceuticals for Steady Growth!

Invest Now

Bafna Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 40.8
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 358
  • P/B Ratio
  • 3.9
  • Average True Range
  • 5.52
  • EPS
  • 4.47
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.36
  • RSI
  • 48.54
  • MFI
  • 60.33

Bafna Pharmaceuticals Financials

Bafna Pharmaceuticals Technicals

EMA & SMA

Current Price
₹151.15
+ 2.76 (1.86%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹152.62
  • 50 Day
  • ₹151.18
  • 100 Day
  • ₹140.32
  • 200 Day
  • ₹122.39

Resistance and Support

149.67 Pivot Speed
  • R3 161.13
  • R2 156.82
  • R1 153.98
  • S1 146.83
  • S2 142.52
  • S3 139.68

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bafna Pharmaceuticals has an operating revenue of Rs. 142.34 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 3% needs improvement, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 17%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 34% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 26% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 48 which is a POOR score indicating inconsistency in earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bafna Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-11 Quarterly Results
2025-08-12 Quarterly Results
2025-05-26 Audited Results
2025-02-06 Quarterly Results
2024-11-11 Quarterly Results

Bafna Pharmaceuticals F&O

Bafna Pharmaceuticals Shareholding Pattern

75%
9.34%
12.04%
3.62%

Bafna Pharmaceuticals FAQs

Bafna Pharmaceuticals share price is ₹151 As on 03 January, 2026 | 07:11

The Market Cap of Bafna Pharmaceuticals is ₹357.6 Cr As on 03 January, 2026 | 07:11

The P/E ratio of Bafna Pharmaceuticals is 40.8 As on 03 January, 2026 | 07:11

The PB ratio of Bafna Pharmaceuticals is 3.9 As on 03 January, 2026 | 07:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23